Key Details
Price
$9.12Annual EPS
-$4.97Annual ROE
-98.01%Beta
2.00Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 23, 2022Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New York Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
FAQ
- What is the primary business of Kodiak Sciences?
- What is the ticker symbol for Kodiak Sciences?
- Does Kodiak Sciences pay dividends?
- What sector is Kodiak Sciences in?
- What industry is Kodiak Sciences in?
- What country is Kodiak Sciences based in?
- When did Kodiak Sciences go public?
- Is Kodiak Sciences in the S&P 500?
- Is Kodiak Sciences in the NASDAQ 100?
- Is Kodiak Sciences in the Dow Jones?
- When was Kodiak Sciences's last earnings report?
- When does Kodiak Sciences report earnings?
- Should I buy Kodiak Sciences stock now?